But I don't think the new formulation is more concentrated, it just has a lecithin emulsifier, correct? I know I am over-simplifying it, but I was not aware that the IPE concentration was any different. So essentially, same active ingredient, just a different delivery system.
I would assume they need a short safety trial, but I doubt they need a REDUCE-It - like trial.
Plus, there is all kinds of data on the internet about the combination of lecithin and EPA. It seems that this is a widely studied mechanism.
As a side-note, some of what I read seems to indicate greater EPA uptake into the brain when combined with lecithin and/or LPC. I wonder if a longer trial (than BRAVE) with the new formulation would prompt better outcomes for ALZ treatment.
Market Data 
Markets 
AI
